ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Rod-Shaped Nanotherapeutics Alleviate Rheumatoid Arthritis by Precisely Disrupting Platelet-Mediated Pathological Crosstalk via a Morphology-Dependent Manner.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rod-Shaped Nanotherapeutics Alleviate Rheumatoid Arthritis by Precisely Disrupting Platelet-Mediated Pathological Crosstalk via a Morphology-Dependent Manner.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
During flares of rheumatoid arthritis (RA), activated platelets (PLTs) amplify inflammatory cascades and drive disease progression by extensively engaging in pro-inflammatory crosstalk with inflammatory cells. Precisely disrupting PLT-mediated pathological cellular crosstalk has emerged as promising therapeutics. Existing PLT-targeting strategies primarily rely on the ligand-mediated recognition, overlooking the hemodynamic behavior of circulating PLTs. Under blood flow, PLTs preferentially roll along vascular walls, while conventional nanocarriers tend to flow along the central axis. This inherent spatial separation limits their targeting efficiency. The optimization of nanoparticle geometry provides a potential solution by enabling precise control over their flow trajectories in circulation. Herein, the study designs fucoidan-functionalized nanoplatforms with different morphologies and comparatively explores their targeting efficiency and regulatory activity in PLTs. In a microfluidic flow model, rod-shaped nanoparticles exhibit markedly enhanced co-localization with endothelial-adherent PLTs. Moreover, these rod-shaped nanoparticles inhibit focal adhesion kinase (FAK) and PI3K/AKT signaling in a morphology-dependent manner, thereby effectively disrupting their pathological cellular crosstalk. In arthritic rats, intravenously administered resveratrol-loaded nanorod (PNR@Res) efficiently binds circulating PLTs and accumulates in inflamed joints, ultimately effectively alleviating RA symptoms. The findings offer insight into how nanoparticle geometry governs cell interactions with circulating PLTs and influences PLT pathological behaviors through a morphology-dependent mechanism in inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.